Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK plc (GSK) Q3 2022 Earnings Call Transcript
02:08pm, Wednesday, 02'nd Nov 2022
GSK plc (NYSE:GSK ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scie
GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat
09:31am, Wednesday, 02'nd Nov 2022
GSK stock jumped Wednesday after the company beat third-quarter forecasts due to strength from specialty medicines and Shingrix. The post GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter
GSK results top City forecasts, UBS sees consensus EPS forecasts rising 3%
08:48am, Wednesday, 02'nd Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK)'s third quarter results beat City expectations according to broker UBS which said turnover of £7,829mln was 7% ahead of consensus with adjusted operating profit of £2,605
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
08:17am, Wednesday, 02'nd Nov 2022
Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK Raises Guidance as Earnings Beat Helps Sure Up Position of CEO
06:01am, Wednesday, 02'nd Nov 2022
GSK became a pure-play pharmaceutical company after spinning off its consumer-health arm earlier this year.
GSK lifts guidance again as bumper third quarter results top City forecasts
04:05am, Wednesday, 02'nd Nov 2022
GSK raised its full year guidance for the second time in three months as soaring sales of its shingles vaccine, Shingrix, drove bumper third quarter results which comfortably topped City expectations.
GSK lifts 2022 view after third quarter sales of $8.99 billion beat forecasts
04:02am, Wednesday, 02'nd Nov 2022
GSK PLC on Wednesday raised its guidance for the full year and posted rising sales for the third quarter that beat expectations.
Wednesday's Agenda- Next to iron out latest figures, GSK expecting disappointing results
11:46am, Tuesday, 01'st Nov 2022
If GSK PLC (LSE:GSK, NYSE:GSK) (GSK PLC (LSE:GSK, NYSE:GSK), GSK PLC (LSE:GSK, NYSE:GSK)) hoped spinning off its consumer household arm Haleon in July would lead to an instant re-rating to a superchar
GSK share price gains momentum ahead of earnings: is it a buy?
12:38pm, Monday, 31'st Oct 2022
GlaxoSmithKline (LON: GSK) share price has made a strong rebound recently as investors buy the company's dip. The shares jumped to a high of 1,433p on Monday, which was the highest level since August
GSK's vaccine for RSV on course to be fast-tracked in Europe
05:00am, Friday, 28'th Oct 2022
GSK is on course to have its new RSV vaccine fast-tracked in Europe after the EMA validated its marketing application based in impressive results from a recent phase III trial. That study showed 83% e
GSK needs to confirm upward curve in next week's update
11:14am, Thursday, 27'th Oct 2022
If GSK hoped spinning off its consumer household arm Haleon in July would lead to an instant re-rating to a supercharged US pharma level, it must be sorely disappointed so far. Shares have barely move
GSK reports mixed outcome from meeting with US Food and Drug Administration
04:34am, Thursday, 27'th Oct 2022
GSK PLC (LSE:GSK, NYSE:GSK) has reported that a US Food and Drugs Administration (FDA) committee voted that the benefits of its drug, daprodustat outweighed risks for adult dialysis patients with ana
GSK to get boost if Zantac ruling reduces liability fears, reckons Citi
10:39am, Wednesday, 19'th Oct 2022
Citibank said it still expects the outcome of the Daubert (evidence admissibility) hearings into Zantac to be favourable to the defendants including GlaxoSmithKline and Sanofi after the initial procee
7 Quality Stocks Selling at a Discount as Q4 Kicks Off
09:21am, Wednesday, 19'th Oct 2022
I know that saying “This time could be different” is dangerous. But still, when it comes to U.S. stocks, I believe that this time could be different and that the long-awaited (by me, at least) bul
GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults
11:17am, Friday, 14'th Oct 2022
GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.
